These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10915092)

  • 61. Current progress in the development of HIV vaccines.
    Spearman P
    Curr Pharm Des; 2006; 12(9):1147-67. PubMed ID: 16515492
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vaccination against HIV.
    Norley S; Kurth R
    Immunobiology; 1992 Feb; 184(2-3):193-207. PubMed ID: 1587543
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HIV-1 superinfection and its implications for vaccine design.
    Chohan BH; Piantadosi A; Overbaugh J
    Curr HIV Res; 2010 Dec; 8(8):596-601. PubMed ID: 21054252
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection.
    Anderson RM; Swinton J; Garnett GP
    Proc Biol Sci; 1995 Aug; 261(1361):147-51. PubMed ID: 7568269
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.
    Gao Y; Tian W; Han X; Gao F
    Front Med; 2017 Dec; 11(4):480-489. PubMed ID: 29170914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cellular immunity for prevention and clearance of HIV infection.
    Kalams SA
    Curr Mol Med; 2003 May; 3(3):195-208. PubMed ID: 12699357
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIV/AIDS vaccine development: are we walking out from the dark?
    Wan YM; Wang YC; Xu JQ
    Chin Med J (Engl); 2010 Dec; 123(23):3489-94. PubMed ID: 22166537
    [No Abstract]   [Full Text] [Related]  

  • 68. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS.
    Cafaro A; Macchia I; Maggiorella MT; Titti F; Ensoli B
    Adv Exp Med Biol; 2009; 655():189-242. PubMed ID: 20047043
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quo vadis: perinatal AIDS issues--2004.
    Weiss SH; Louria DB
    Clin Perinatol; 1994 Mar; 21(1):179-98. PubMed ID: 8013184
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Vaccine for human immunodeficiency virus (HIV)--relevance of these days].
    Laiskonis A; Pukenyte E
    Medicina (Kaunas); 2005; 41(2):93-9. PubMed ID: 15758574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CEL-SCI offers South Africa a free license to use AIDS vaccine.
    AIDS Read; 2000 Jun; 10(6):340. PubMed ID: 10881364
    [No Abstract]   [Full Text] [Related]  

  • 72. Systems biology and the quest for correlates of protection to guide the development of an HIV vaccine.
    Kuri-Cervantes L; Fourati S; Canderan G; Sekaly RP
    Curr Opin Immunol; 2016 Aug; 41():91-97. PubMed ID: 27392184
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.
    Koup RA; Graham BS; Douek DC
    Nat Rev Immunol; 2011 Jan; 11(1):65-70. PubMed ID: 21164527
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 2009--a banner year in AIDS vaccine research and development.
    Kresge KJ
    IAVI Rep; 2009; 13(6):2. PubMed ID: 20210215
    [No Abstract]   [Full Text] [Related]  

  • 75. Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine.
    Smith SM; Khoroshev M; Marx PA; Orenstein J; Jeang KT
    J Biol Chem; 2001 Aug; 276(34):32184-90. PubMed ID: 11397795
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Seeking new pathways for HIV vaccine discovery.
    Flores J
    Future Microbiol; 2009 Feb; 4(1):1-7. PubMed ID: 19207094
    [No Abstract]   [Full Text] [Related]  

  • 77. Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative.
    Tucker TJ; Mazithulela G
    BMJ; 2004 Aug; 329(7463):454-6. PubMed ID: 15321907
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Highlights of AIDS vaccine meeting.
    Doepel LK
    NIAID AIDS Agenda; 1996 Mar; ():16-9. PubMed ID: 11363795
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A mathematical model of vaccination against HIV to prevent the development of AIDS.
    Nowak MA; McLean AR
    Proc Biol Sci; 1991 Nov; 246(1316):141-6. PubMed ID: 1685238
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How Basic Immunological Principles May Instruct the Design of a Successful HIV-Type 1 Vaccine.
    Slobod KS; Hurwitz JL
    Viral Immunol; 2020 Apr; 33(3):233-236. PubMed ID: 32286171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.